A Double-Blind Comparison of Moxonidine and Atenolol in the Management of Patients with Mild-to-Moderate Hypertension

The safety and efficacy f moxonidine, a new imidazoline receptor modulator, were compared with those of atenolol in 63 patients with mild-to-moderate essential hypertension in a multicenter, randomized, double-blind, parallel-group trial. The study consisted of a 4-week single-blind placebo run-in phase, an 8-week doule-blind active therapy period, and a 2-week single-blind washout phase on placebo